HomeCompareMAHLY vs JNJ

MAHLY vs JNJ: Dividend Comparison 2026

MAHLY yields 1.85% · JNJ yields 2.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MAHLY wins by $67.7K in total portfolio value
10 years
MAHLY
MAHLY
● Live price
1.85%
Share price
$17.68
Annual div
$0.33
5Y div CAGR
50.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$98.0K
Annual income
$34,756.80
Full MAHLY calculator →
JNJ
Johnson & Johnson
● Live price
2.13%
Share price
$244.44
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.3K
Annual income
$4,689.40
Full JNJ calculator →

Portfolio growth — MAHLY vs JNJ

📍 MAHLY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMAHLYJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MAHLY + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MAHLY pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MAHLY
Annual income on $10K today (after 15% tax)
$157.33/yr
After 10yr DRIP, annual income (after tax)
$29,543.28/yr
JNJ
Annual income on $10K today (after 15% tax)
$180.82/yr
After 10yr DRIP, annual income (after tax)
$3,985.99/yr
At 15% tax rate, MAHLY beats the other by $25,557.29/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MAHLY + JNJ for your $10,000?

MAHLY: 50%JNJ: 50%
100% JNJ50/50100% MAHLY
Portfolio after 10yr
$64.1K
Annual income
$19,723.10/yr
Blended yield
30.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MAHLY
No analyst data
Altman Z
2.8
Piotroski
5/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-6.4% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MAHLY buys
0
JNJ buys
8
PoliticianChamberTickerTypeAmountDate
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002026-01-23
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-12-18
Lloyd Doggett🏢 House$JNJ▲ Buy$1,001 - $15,0002025-12-09
Thomas H. Kean🏢 House$JNJ▼ Sell$15,001 - $50,0002025-11-20
Julie Johnson🏢 House$JNJ▼ Sell$1,001 - $15,0002025-11-13
Rich McCormick🏢 House$JNJ▲ Buy$1,001 - $15,0002025-11-05
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Ro Khanna🏢 House$JNJ▲ Buy$1,001 - $15,0002025-10-30
Jared Moskowitz🏢 House$JNJ▼ Sell$1,001 - $15,0002025-10-10
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMAHLYJNJ
Forward yield1.85%2.13%
Annual dividend / share$0.33$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR50.2%28%
Portfolio after 10y$98.0K$30.3K
Annual income after 10y$34,756.80$4,689.40
Total dividends collected$71.8K$15.4K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MAHLY vs JNJ ($10,000, DRIP)

YearMAHLY PortfolioMAHLY Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$10,978$278.01$10,592$272.30+$386.00MAHLY
2$12,175$428.41$11,289$357.73+$886.00MAHLY
3$13,694$666.95$12,123$472.89+$1.6KMAHLY
4$15,706$1,053.04$13,141$629.86+$2.6KMAHLY
5$18,500$1,695.34$14,408$846.81+$4.1KMAHLY
6$22,599$2,803.28$16,021$1,151.60+$6.6KMAHLY
7$28,987$4,806.79$18,122$1,588.22+$10.9KMAHLY
8$39,672$8,655.00$20,930$2,228.20+$18.7KMAHLY
9$59,076$16,627.33$24,792$3,191.91+$34.3KMAHLY
10$97,968$34,756.80$30,274$4,689.40+$67.7KMAHLY

MAHLY vs JNJ: Complete Analysis 2026

MAHLYStock

Medipal Holdings Corporation engages in the prescription pharmaceutical wholesale business in Japan. It procures healthcare products related to diagnostics, testing, treatment, and administration comprises medical equipment and medical materials, and clinical diagnostic reagents for use from the pre-symptomatic stage; handles PMS services on contract for manufacturers; and invests in orphan drugs and other products. The company is also involved in the wholesale of cosmetics, daily necessities, and OTC pharmaceuticals; animal health products for companion animals; food processing raw materials for agriculture, fisheries, and livestock; and livestock feed additives, seasonings, veterinary medical equipment, packaging materials, industrial chemicals, and other products. In addition, it engages in the contract-based epidemiological studies, clinical studies, etc.; creation of a computerized medical supply database and master product databases for medical facilities; health insurance claims reviews, medical coding dispatch, outsourcing, and remote education activities; life and non-life insurance agency business; cleaning management; management and operation of distribution centers; commissioned delivery and worker dispatch business; and planning, management, administration, and product and service development for the class A health dispensing pharmacies service brand. Medipal Holdings Corporation serves hospitals, clinics, dispensing pharmacies, drugstores, home centers, convenience stores, supermarkets, discount stores, animal hospitals, livestock and fishery businesses, and processed food manufacturers. The company was formerly known as Mediceo Paltac Holdings Co., Ltd. and changed its name to Medipal Holdings Corporation in October 2009. Medipal Holdings Corporation was founded in 1898 and is headquartered in Tokyo, Japan.

Full MAHLY Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MAHLY vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MAHLY vs SCHDMAHLY vs JEPIMAHLY vs OMAHLY vs KOMAHLY vs MAINMAHLY vs ABBVMAHLY vs MRKMAHLY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.